13 completed, 1 terminated, 1 unknown, 1 withdrawn. 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 13, Terminated 1, Unknown 1, Withdrawn 1 |
Follow Duration of Therapy: new trials by email Literature Review of Duration of Therapy trials Research Report on Duration of Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia EDP-420 / Duration of Treatment - 3 days, Telithromycin / Duration of Treatment - 7 days - Community Acquired Pneumonia | Phase 2 | Unknown | Enanta Pharmaceuticals, Inc | 250 | 2005-12-01 | 2006-09-19 |
| MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED) MK0928, gaboxadol / Duration of Treatment 3 Weeks, Placebo / Duration of Treatment 3 Weeks - Primary Insomnia | Phase 2 | Completed | H. Lundbeck A/S | 520 | 2005-11-01 | 2015-01-14 |
| Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED) MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose), Placebo / Duration of Treatment: 2 days for screening period - Primary Insomnia | Phase 2 | Terminated | H. Lundbeck A/S | 50 | 2005-11-01 | 2015-01-14 |
| An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013) MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months - B-cell Lymphoma | Phase 2 | Completed | Merck Sharp & Dohme LLC | 18 | 2005-05-01 | 2017-04-07 |
| MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED) Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks, MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks, Comparator : niacin / Duraton of Treatment: 4 Weeks - Hypercholesterolemia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 407 | 2005-04-01 | 2017-04-07 |
| Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months - Cutaneous T-cell Lymphoma, Sezary Syndrome | Phase 2 | Completed | Merck Sharp & Dohme LLC | 74 | 2005-02-03 | 2017-04-05 |
| Safety and Pk Study in 1- to 3- Month-Old Children With Bronchiolitis (0476-297) MK0476, Montelukast Sodium /Duration of Treatment : 14 Days - Bronchiolitis | Phase 2 | Completed | Organon and Co | 12 | 2004-12-01 | 2024-08-15 |
| Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083) MK0663, etoricoxib / Duration of Treatment: 4 weeks - Bone Neoplasms | Phase 2 | Withdrawn | Organon and Co | 2004-11-01 | 2022-02-16 | |
| MK0524A Phase IIb Study (0524A-011)(COMPLETED) Comparator: niacin / Duration of Treatment: 17 Weeks, MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks - Flushing | Phase 2 | Completed | Merck Sharp & Dohme LLC | 154 | 2004-08-01 | 2015-08-25 |
| Endpoint Validation Study (0524A-015) MK0524A, /Duration of Treatment : 8 Weeks, Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks - Flushing | Phase 2 | Completed | Merck Sharp & Dohme LLC | 165 | 2004-08-01 | 2017-02-17 |
| MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043) MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks, Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks - Type 2 Diabetes Mellitus | Phase 2 | Completed | Merck Sharp & Dohme LLC | 126 | 2004-06-01 | 2017-04-04 |
| Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008) MK0812 / Duration of Treatment: 12 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks - Arthritis, Rheumatoid | Phase 2 | Completed | Merck Sharp & Dohme LLC | 149 | 2004-06-01 | 2015-10-20 |
| MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378) MK0476, montelukast sodium / Duration of Treatment: 2 Weeks, Comparator: placebo / Duration of Treatment: 2 Weeks - Rhinitis Allergic | Phase 2 | Completed | Organon and Co | 945 | 2004-02-01 | 2024-08-15 |
| A Study of MK0431 in Patients With Type 2 Diabetes (0431-010) MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks - Diabetes Mellitus, Type II | Phase 2 | Completed | Merck Sharp & Dohme LLC | 743 | 2003-05-13 | 2017-03-28 |
| Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036) MK0826, ertapenem sodium /Duration of Treatment: 14 Days, Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days - Urinary Tract Infections, Bacterial Pneumonia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 400 | 2002-01-01 | 2017-02-17 |
| A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED) MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks, Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks - HIV Infections | Phase 2 | Completed | Merck Sharp & Dohme LLC | 330 | 2001-01-01 | 2017-02-17 |
Diabetes Mellitus, Type 2 (2) · Flushing (2) · Sleep Initiation and Maintenance Disorders (2) · Arthritis, Rheumatoid (1) · Bone Neoplasms (1) · Bronchiolitis (1) · Community-Acquired Pneumonia (1) · HIV Infections (1) · Hypercholesterolemia (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Pneumonia, Bacterial (1) · Rhinitis, Allergic, Perennial (1)
Merck Sharp & Dohme LLC (10) · Organon and Co (3) · H. Lundbeck A/S (2) · Enanta Pharmaceuticals, Inc (1)
United States (1)